Possibly due to mistargeted localization and the lack of suitable signalling co-factors on late endosomes, HER2 signalling to the PI3K/AKT/mTOR proliferative pathway was decreased in SORLA-silenced breast cancer cells. Here, MTOR is linked to breast carcinoma.